We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 31.13 | 4.24% | 766.10 | 766.99 | 736.00 | 738.04 | 3,397,607 | 01:00:00 |
From May 2021 to May 2024
By Josh Beckerman
The U.S. Food and Drug Administration expanded its emergency use authorization for a combination of two Eli Lilly & Co. monoclonal antibodies for treating mild to moderate Covid-19, expanding authorization to all ages including newborns for those who are at high risk for progression to severe Covid-19.
The combination of bamlanivimab and etesevimab was previously authorized for people 12 years of age and older weighing at least 40 kilograms.
Lilly said it is "working quickly to understand neutralization activity of our therapies on the Omicron variant of concern."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 03, 2021 15:18 ET (20:18 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
